tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
PremiumCompany AnnouncementsAligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
22d ago
Aligos Therapeutics appoints James Hassard as EVP, CCO
Premium
The Fly
Aligos Therapeutics appoints James Hassard as EVP, CCO
24d ago
Aligos Therapeutics initiated with a Buy at UBS
Premium
The Fly
Aligos Therapeutics initiated with a Buy at UBS
30d ago
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe FlyAligos Therapeutics announces inducement grants under Nasdaq listing rule
3M ago
Aligos Therapeutics presents data from eight presentations at AASLD
Premium
The Fly
Aligos Therapeutics presents data from eight presentations at AASLD
3M ago
Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating
Premium
Ratings
Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating
3M ago
Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium
PremiumThe FlyAligos Therapeutics receives USAN council approval for pevifoscorvir sodium
4M ago
Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
Premium
Ratings
Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
4M ago
Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target
Premium
Ratings
Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100